Table 1 Final clinical outcomes
From: OCT macular changes in type 1 ROP following Ranibizumab injections
ROP characteristics (1 month post IVI) | |
|---|---|
Stage 0, No. of eyes (%) | 12, (50%) |
Stage 1, No. of eyes (%) | 5, (20.83%) |
Stage 2, No. of eyes (%) | 7, (29.17%) |
Zone II, No. of eyes (%) | 23, (95.83%) |
Zone III, No. of eyes (%) | 1, (4.17%) |
Regressed plus, No. of eyes (%) | 2, (8.3%) |
No plus, No. of eyes (%) | 20, (83.3%) |
Pre-plus/plus, No. of eyes (%) | 2, (8.3%) |